Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Breaching the protective cancer stroma with radiotherapy-responsive liposomes

Project description

Radiotherapy for precision drug delivery

Liposomes are lipid-based artificial vesicles that have been widely used for the delivery of chemotherapy drugs. However, controlling precisely when and where drugs are released within tumours remains a major challenge. The ERC-funded RADIOCONTROL project develops a novel strategy involving the use of nanomaterials that absorb radiation. The goal is to embed these nanomaterials within liposomes, enabling X-rays to trigger drug release directly within tumour tissue. The approach involves the generation of reactive oxygen species, which break open the liposomes and improve drug release into tumours. The project focuses on pancreatic cancer, one of the most treatment-resistant cancers. If successful, radiation-controlled liposomal drug delivery could significantly advance treatment options for many cancer patients.

Objective

Liposomes have been the most successful type of nanomedicine for cancer patients, playing a leading role in improving the tolerability of chemotherapeutics. However, to advance the success of liposomal drug delivery and cancer treatment, new approaches to physically trigger drug release in cancer tissues and increase the permeability of the protective cancer stroma are needed. This project will investigate whether radiocatalytic nanomaterials can be integrated in liposomes for spatiotemporal-controlled drug release, the alleviation of cancer desmoplasia, and improved efficacy of co-encapsulated drugs.

Liposomes will be composed of oxidation-susceptible phospholipids that encapsulate hydrophilic drugs in their aqueous core. Radiation-absorbing nanomaterials will be included in the liposomes to produce high levels of reactive oxygen species when activated by X-rays. This will oxidize the liposomes and facilitate the release of the encapsulated drugs. Simultaneously, the cytotoxicity of the oxidants is expected to reduce the high cell densities in the tumor periphery, enabling the therapeutics to deeply permeate the cancer tissues following their release. This customizable strategy will be developed in the context of pancreatic cancer, a chemoresistant form of cancer with poor survival rates. This project develops a multidisciplinary approach to investigate the physicochemical mechanisms of radiotherapy-induced drug release, adaptive optics microscopy to study tissue permeability in 3D cultures of desmoplastic pancreatic cancer, and multimodal in vivo imaging to uncover the therapeutic potential and mechanisms.

Radiotherapy-controlled drug release from liposomes is a ground-breaking novel concept, and its capacity to increase cancer tissue permeability has never before been demonstrated. When successful, new avenues for controlled liposomal drug delivery will emerge that can significantly advance the standard-of-care for many cancer patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 1 942 158,00
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 1 942 158,00

Beneficiaries (1)